Citations

Clear

511 citation(s) found for "Seth, N".

Spinal pathologies and management strategies associated with cervical angina (pseudoangina): a systematic review
Brown, Nolan J. , Ransom, Seth C. , Sahyouni, Ronald , Ransom, Ryan Chase, Shahrestani, Shane , Lien, Brian V. , Tafreshi, Ali R., Ransom, Ryan C.

Mayo Clinic

Journal of Neurosurgery: Spine | December 4, 2020 | Volume: 34 | Issue: 3 | Pages: 506-513

10.3171/2020.7.spine20866 | PMID 33276331 Get It

OBJECTIVECervical angina, or pseudoangina pectoris, is a noncardiac syndrome of chest pain that often mimics angina pectoris but is a disease of the spine. Diagnosis of cervical angina can be difficult and is often overlooked, although once identified, it can be successfully managed through conservative therapies and/or a variety of surgical interventions. Ultimately, cervical angina is an important component of the list of differential diagnoses in noncardiac chest pain. In the present study, the authors report the first comprehensive systematic review of the range of cervical and thoracic pathologies associated with cervical angina, as well as the different treatment methods used to manage this condition.METHODSA systematic review was performed according to PRISMA guidelines and using PubMed, Web of Science, and Cochrane databases from database inception to April 29, 2020, to identify studies describing spinal pathologies related to cervical angina. The following Boolean search was performed: (“cervical” OR “thoracic”) AND (“angina” OR “chest pain”) AND (“herniation” OR “OPLL”). Variables extracted included patient demographics, cervical angina pain location, pathology and duration of symptoms, treatment and/or management method, and posttreatment pain relief.RESULTSUpon careful screening, 22 articles published between 1976 and 2020 met the study’s inclusion/exclusion criteria, including 5 case series, 12 case reports, and 5 retrospective cohort studies. These studies featured a total of 1100 patients, of which 95 met inclusion criteria (mean patient age 51.7 years, age range 24–86 years; 53.6% male). Collectively, symptom durations ranged from 1.5 days to 90 months. Cervical herniation (72.6%) accounted for the majority of cervical angina cases, and surgical interventions (84.4%) predominated over physical therapy (13.0%) and medical management strategies (9.1%). Every patient assessed at follow-up reported relief from symptoms related to cervical angina.CONCLUSIONSCervical angina is a noncardiac syndrome of chest pain associated with a broad range of cervical and thoracic spinal pathologies, the most common of which is cervical disc herniation. Although difficult to diagnose, it can be successfully treated when identified through first-line conservative management or surgical interventions in refractory cases.
Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
Polydefkis, Michael , Sekijima, Yoshiki , Sweetser, Marianne T., Arum, Seth, Wang, J.J, White, Matthew T. , Maurer, Mathew S. , Gillmore, Julian D. , Berk, John L. , Dispenzieri, Angela , González-Duarte, Alejandra , Maurer, Mathew S

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.2129 Get It

Abstract Background/Introduction Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, life-threatening disease; the majority of patients develop a mixed phenotype of polyneuropathy and cardiomyopathy. Patisiran halted or reversed polyneuropathy and improved quality of life in the Phase 3 (APOLLO) study. In a prespecified cardiac subpopulation of APOLLO, patisiran also improved cardiac structure and function versus placebo. Purpose To describe the long-term comprehensive, integrated safety data from the patisiran clinical development program in patients with hATTR amyloidosis with polyneuropathy. Methods Safety data as of October 7, 2019 from the Phase 2 Open-Label Extension (OLE) (NCT01961921), Phase 3 APOLLO (NCT01960348), and ongoing Global OLE (NCT02510261) studies were analysed. Results Across the three studies, 224 patients received patisiran for a mean (range) of 43.6 (0.7–71.7) months, with a cumulative 813.9 patient-years of exposure; 105 (46.9%) patients received patisiran for ≥4 years and 35 (15.6%) patients received patisiran for ≥5 years. In this cohort, 149 (66.5%) had medical histories of cardiac disorders per MedDRA System Organ Class (SOC), which may be reflective of a mixed phenotype in some patients. A total of 222 (99.1%) patients experienced at least one adverse event (AE) and 132 (58.9%) patients experienced at least one serious AE. AEs considered to be related to patisiran and occurring in >5% of patients included infusion-related reactions (IRRs) (25.9%) and diarrhoea (6.3%). Cardiac AEs occurring in >5% of patients included atrial fibrillation (10.7%) and cardiac failure (7.6%). Amongst all patients, the exposure-adjusted mortality rate was 4.3 deaths per 100 patient-years. Conclusions Patients with hATTR amyloidosis with polyneuropathy in the patisiran clinical development program represent those with the longest treatment with an RNAi therapeutic, including more than 15% of patients receiving patisiran for ≥5 years. Patisiran continues to demonstrate a positive benefit:risk profile in patients with hATTR amyloidosis with polyneuropathy. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Alnylam Pharmaceuticals
Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors
Force, US Preventive Services Task, Krist, Alex H. , Davidson, Karina W. , Mangione, Carol M. , Cabana, Michael D. , Caughey, Aaron B. , Donahue, Katrina E , Epling, John W. , Kubik, Martha , Landefeld, Seth, Ogedegbe, Gbenga, Silverstein, Michael, Tseng, Chien‐Wen , Wong, John B. , Doubeni, Chyke A. , Krist, Alex , Davidson, Karina , Force, US Preventive Services Task, Barry, Michael J. , Pbert, Lori A. , Simon, Melissa Andrea

Mayo Clinic

JAMA | November 24, 2020 | Volume: 324 | Issue: 20 | Pages: 2069

10.1001/jama.2020.21749 | PMID 33231670 Get It

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Somaiah, Neeta , Chawla, Sant P. , Block, Matthew S. , Morris, John C. , Kim, Joseph W. , Druta, Mihaela , Sankhala, Kamalesh K. , Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Tuballes, Kevin , Yishak, Mahlet, Yakovich, Adam J., Meulen, Jan ter , Chen, Michael , Bohac, Chet, Gnjatic, Sacha , Jones, Robin L , Khanh, T. , Kim-Schulze, Seunghee , Lu, Hailing , Kenney, Richard T , Pollack, Seth M.

Mayo Clinic

OncoImmunology | November 19, 2020 | Volume: 9 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1847846 | PMID 33312760 Get It

High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury: Results from the TRACK-TBI Study
Xu, Linda , Yue, John K. , Korley, Frederick K. , Puccio, Ava M. , Yuh, Esther L. , Sun, Xiaoying, Rabinowitz, Miri, Vassar, Mary J. , Taylor, Sabrina R. , Winkler, Ethan A. , Puffer, Ross C. , Deng, Hansen , McCrea, Michael , Robertson, Claudia S. , Levin, Harvey S. , Dikmen, Sureyya, Okonkwo, David O. , Jain, Sonia , Manley, Geoffrey T. , Investigators, The TRACK-TBI, Boase, Kim, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Duhaime, Ann-Christine, Ellenbogen, Richard, Feeser, V. Ramana, Ferguson, Adam R., Gaudette, Etienne, González, Luis, Gopinath, Shankar, Gullapalli, Rao, Hemphill, J. Claude, Hotz, Gillian , Kramer, Joel H. , Kreitzer, Natalie, Lindsell, Chris, Machamer, Joan , Madden, Christopher , McAllister, Thomas W. , Merchant, Randall, Noël, Florence, Palacios, Eva , Perl, Daniel, Rosand, Jonathan, Satris, Gabriella, Seabury, Seth, Toga, Arthur W. , Adeoye, Alex VaOpeolu, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Ferguson, Adam R., Gaudette, Etienne, Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Merchant, Randall, Perl, Daniel, Rosand, Jonathan, Seabury, Seth, Valadka, Alex B. , Vespa, Paul , Zafonte, Ross , Hemphill, J. Claude , Ferguson, Adam R. , Kreitzer, Natalie , Stein, Murray B. , Temkin, Nancy R. , Giacino, Joseph T. , Mukherjee, Pratik , Wang, Kevin , Markowitz, Amy J. , Diaz‐Arrastia, Ramon , Investigators, The TRACK-TBI, Adeoye, Opeolu M , Badjatia, Neeraj , Bodien, Yelena, Bullock, M. Ross, Chesnut, Randall Matthew , Corrigan, John D. , Crawford, Karen, Ferguson, Adam R., Foreman, Brandon , Gardner, Raquel C. , Gaudette, Etienne, Goldman, Dana P. , Gopinath, Shankar P. , Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Martin, Alastair J. , Merchant, Randall, Nelson, Lindsay D. , Ngwenya, Laura Benjamin , Perl, Daniel, Rosand, Jonathan, Sander, Angelle M. , Schnyer, David M. , Seabury, Seth, Bodien, Yelena, Bullock, M. Ross, Crawford, Karen, Ferguson, Adam R., Gaudette, Etienne, Gullapalli, Rao, Hemphill, J. Claude, Kreitzer, Natalie, Lindsell, Chris, Merchant, Randall, Perl, Daniel, Rosand, Jonathan, Seabury, Seth

Mayo Clinic

Journal of Neurotrauma | November 9, 2020 | Volume: 38 | Issue: 7 | Pages: 918-927

10.1089/neu.2020.7177 | PMID 33161875 Get It

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
Hess, Brian , Giri, Anshu , Patel, Krina K. , Nowakowski, Grzegorz S. , Maliske, Seth , Hill, Brian T. , Garcia, Alex, Maddocks, Kami J. , Wagner‐Johnston, Nina D. , Messmer, Marcus , Alderuccio, Juan Pablo , Lossos, Izidore S., Nathan, Sunita , Portell, Craig A. , Ayers, Emily C. , Portell, Craig A , Park, Yeonhee , Link, Brian K. , Fortin, Sonia, Chavez, Julio C , Saeed, Hayder , Hanel, Walter G. , Kahl, Brad S. , Watkins, Marcus P. , Lossos, Izidore S. , Orellana‐Noia, Victor M. , Landsburg, Daniel J. , Castillo, Jorge J.

Mayo Clinic

Blood | November 4, 2020 | Volume: 136 | Issue: Supplement 1 | Pages: 15-16

10.1182/blood-2020-138536 Get It

Background: Plasmablastic lymphoma (PBL) is a rare subtype of Non-Hodgkin Lymphoma with a well-known association with HIV infection. The outcomes of PBL patients are typically described with high relapse rates and poor prognosis. (Loghavi S, J Hematol Oncol. 2015; Morscio J, Am J of Pathol. 2014; Castillo JJ, Clin Lymphoma Myeloma Leuk. 2011; Castillo JJ, Am J Hematol. 2008) There has been a paucity of data suggesting that limited stage disease (Ann Arbor stage I-II) may have a more favorable prognosis. However, due to the rarity of this disease there have been no large-scale reviews to confirm this. Thus, many patients with limited stage disease are subject to the aggressive therapy recommendations based on the poor outcomes of PBL patients as a whole. (Loghavi S, J Hematol Oncol. 2015; NCCN Guidelines, version 2.2020; Al-Malki MM, BBMT. 2014) We attempted to determine the treatment patterns and outcomes of patients with limited stage PBL. Methods: We conducted a multi-center (13 US academic centers) retrospective study of patients with limited stage (Ann Arbor stage I-II) Plasmablastic lymphoma. Determination of limited stage and diagnosis of PBL was determined by the investigators at each individual center. Patients diagnosed between 1/1/1990 and 6/1/2018 were included. Baseline demographic, clinical, laboratory, pathology, and outcomes data were extracted by retrospective chart review. Kaplan Meier was utilized for time to event analysis. Results: Baseline characteristics are included in table 1. A total of 80 patients were identified with limited stage disease. With a median follow up of 34 months the 3-yr Progression free survival (PFS) and overall survival (OS) was 71.9% and 78.7% respectively (Figure 1A and 1B). Patients that received frontline chemotherapy with (n=29) and without RT (n=36) had a 3-yr PFS and OS of 84.6% and 96.2% as compared to 64.5% and 70.8%, respectively (Figure 2A and 2B; Figure 3A and 3B). The Hazard ratio (HR) for PFS and OS for chemo (reference) vs chemo-RT was 0.47 (95% CI 0.18-1.3; P=0.131) and 0.18 (95% CI 0.04-0.84; p=0.029) respectively. The HR for PFS and OS for CHOP (n=14, reference) vs EPOCH (n=33) based regimens was 0.37 (95% CI 0.11-1.2; p=0.106) and 0.36 (95% CI 0.079-1.6; p=0.182) respectively. Patients with stage I/IE disease (n=56) had a 3-yr PFS and OS of 73.1% and 81.2% respectively. Patients with stage II/IIE disease (n=24) had a 3-yr PFS and OS of 69.3% and 73.4% respectively. Patients that received aggressive treatment (n=17) with Hyper-CVAD based regimens and/or Auto-SCT as consolidation had a 3-yr PFS and OS of 63.6% and 72.7% respectively. Patients with concomitant HIV (n=16) had a 3-yr PFS and OS of 80.8% and 77.4% respectively. Seven patients received RT alone and 6 patients had surgical resection alone as frontline therapy; 1 patient received no therapy; 1 patient received HAART therapy only and remains in CR without any other treatment for PBL 29 months after diagnosis. There were 8 deaths (10%) related to PBL, 3 deaths (4%) related to treatment of PBL (2 during frontline chemo and 1 upon relapse with salvage chemo), and 9 deaths (11%) related to other causes. The 3-yr lymphoma free survival (LFS) of the entire cohort, pts receiving chemo alone, and pts receiving chemo-RT (without including treatment related mortality (TRM) as an event) was 89.1%, 85.2%, and 100% respectively. The 3-yr LFS survival of the entire cohort, pts receiving chemo alone, and pts receiving chemo-RT (including TRM as an event) was 85.1%, 80.0%, and 96.2% respectively. Discussion: Here we report the largest review to our knowledge of limited stage PBL. Outcomes appear to be excellent with 3-yr PFS and OS of 71.9% and 78.7% respectively and a 3-yr LFS of 89.1% (85.1% when attributing TRM as an event). There was no obvious benefit to receiving aggressive therapy with H-CVAD based regimens and/or Auto-SCT. Although this is a small, uncontrolled sample size the HR for OS was improved in patients receiving frontline chemo-RT vs chemo alone 0.18 (95% CI 0.04-0.84; p=0.029). However, this did not take into account TRM with or progression while receiving frontline chemotherapy. Patients who were HIV+ had similar PFS and OS outcomes compared to the entire cohort. This retrospective study clearly demonstrates the favorable outcomes in this patient population, especially in those able to receive definitive therapy for their disease. Disclosures Hess: ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS, AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Patel:Takeda: Consultancy, Research Funding; Precision Biosciences: Research Funding; Nektar: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Poseida: Research Funding; Cellectis: Research Funding; Oncopeptides: Consultancy; Janssen: Consultancy, Research Funding. Nowakowski:Nanostrings: Research Funding; Seattle Genetics: Consultancy; Curis: Consultancy; Ryvu: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other; Kymera: Consultancy; Denovo: Consultancy; Kite: Consultancy; Celgene/BMS: Consultancy, Research Funding; Roche: Consultancy, Research Funding; MorphoSys: Consultancy, Research Funding. Chavez:Bayer: Consultancy; AbbVie: Consultancy; BeiGene: Speakers Bureau; Morphosys: Consultancy, Speakers Bureau; Merck: Research Funding; AstraZeneca: Speakers Bureau; Celgene: Consultancy; Genentech: Speakers Bureau; Epizyme: Speakers Bureau; Gilead: Consultancy; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Speakers Bureau; Karyopharm: Consultancy; Verastem: Consultancy; Pfizer: Consultancy. Hill:Beigene: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Takeda: Research Funding; AstraZenica: Consultancy, Honoraria, Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding. Maddocks:Pharmacyclics: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Karyopharm: Consultancy; ADC Therapeutics, AstraZeneca: Consultancy; BMS: Consultancy, Research Funding. Wagner-Johnston:ADC Therapeutics, Regeneron, CALIB-R, Verastem: Membership on an entity's Board of Directors or advisory committees. Kahl:AstraZeneca Pharmaceuticals LP: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy; Pharmacyclics LLC: Consultancy; Genentech: Consultancy; Acerta: Consultancy, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Consultancy; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche Laboratories Inc: Consultancy. Alderuccio:ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Forma Therapeutics: Other: Family member; Agios Pharmaceuticals: Other: Family member; Oncinfo: Honoraria; Inovio Pharmaceuticals: Other: Family member; Foundation Medicine: Other: Family member; Puma Biotechnology: Other: Family member; OncLive: Honoraria. Lossos:Janssen Biotech: Honoraria; Verastem: Consultancy, Honoraria; Janssen Scientific: Consultancy, Other; Seattle Genetics: Consultancy, Other; Stanford University: Patents & Royalties; NCI: Research Funding. Portell:Bayer: Consultancy; BeiGene: Consultancy, Research Funding; Kite: Consultancy, Research Funding; Acerta/AstraZeneca: Research Funding; Amgen: Consultancy; Janssen: Consultancy; Pharmacyclics: Consultancy; AbbVie: Research Funding; TG Therapeutics: Research Funding; Infinity: Research Funding; Roche/Genentech: Consultancy, Research Funding; Xencor: Research Funding. Landsburg:Celgene: Membership on an entity's Board of Directors or advisory committees; Triphase: Research Funding; Takeda: Research Funding; Curis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Speakers Bureau. Castillo:TG Therapeutics: Research Funding; Beigene: Consultancy, Research Funding; Kymera: Consultancy; Janssen: Consultancy, Research Funding; Abbvie: Research Funding; Pharmacyclics: Consultancy, Research Funding.
Expression of the regulated isoform of the electrogenic Na+/HCO3− cotransporter, NBCe1, is enriched in pacemaker interstitial cells of Cajal
Aguilar, Maria Gabriela Colmenares , Mazzone, Amelia , Eisenman, Seth T., Strege, Peter R. , Bernard, Cheryl E., Holmes, Heather L. , Romero, Michael F. , Farrugia, Gianrico , Gibbons, Simon J. , Colmenares Aguilar, Maria-Gabriela, Gibbons, S J , Romero, Michael F , Strege, Peter R , Mazzone, Amelia

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | October 28, 2020 | Volume: 320 | Issue: 1 | Pages: G93-G107

10.1152/ajpgi.00255.2020 | PMID 33112159 Get It

In this study, we show that the electrogenic Na+/HCO3− cotransporter, NBCe1/Slc4a4, is expressed in subtypes of interstitial cells of Cajal (ICCs) responsible for electrical slow wave generation throughout the mouse gastrointestinal tract and is absent in other types of ICCs. The transcripts of Slc4a4 expressed in mouse ICCs and human gastrointestinal smooth muscle are the regulated isoforms. This indicates a key role for HCO3- transport in generation of gastrointestinal motility patterns.
S1626 A Case of Colorectal Cancer and Serrated Polyposis Syndrome in Hodgkin Lymphoma Survivor
Choi, Chansong , Sweetser, Seth

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S834-S835

10.14309/01.ajg.0000708552.21649.bf Get It

S3138 Participation Rates and Predictors in Non-Endoscopic Barrett’s Esophagus Detection Sponge on a String (SOS) Trials
Lui, Jacob , Codipilly, Don C. , Johnson, Michele L., Lansing, Ramona, Hemminger, Lois L., Cayer, Frances K., Broderick, Brendan T., Burger, Kelli N. , Wolfsen, Herbert C. , Ramirez, Francisco C. , Katzka, David A. , Iyer, Prasad G. , Slettedahl, Seth W. , Mahoney, Douglas W. , Doering, Karen A. , Foote, Patrick H. , Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S4-S5

10.14309/01.ajg.0000714600.12161.6f Get It

S0308 Prep-Free Screening Capsule to Redefine Colorectal Cancer Screening and Prevention
Gross, Seth A. , Rajan, Elizabeth , Rainis, Tova , Moshkovitz, Menachem, Half, Elizabeth , Gralnek, Ian M. , Shpak, Beni, AbuFrecha, Naim, Ringel, Yehuda, Binyaminov, Fabiana, Hansel, Stephanie L. , Arber, Nadir

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S150-S151

10.14309/01.ajg.0000703280.51594.7d Get It